SCYX — SCYNEXIS INC

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1178253 ·
Last close
$2.85
Market Cap
$28.37M
52W High
$9.12
52W Low
$2.70
ADV30
82,124
Next earnings
2026-11-05

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -9,761,000 -8,458,000 67,951,000 8,228,000 8,904,000
Jun 2026 235,000 — -7,775,000 7,397,000 74,970,000 10,487,000 8,040,000
Mar 2026 0 — -16,939,000 -21,299,000 77,626,000 36,671,000 36,319,000
Dec 2025 18,646,000 — 10,521,000 12,258,000 59,027,000 21,259,000 9,651,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-13,309,000
Investing CF
$-24,690,000
Financing CF
$37,411,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.20
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-399,046,000
Inventory
—
Receivables
$0
ST Investments
$43,596,000
EBIT TTM
$-10,235,000
Pretax Income TTM
$-10,235,000
Interest Exp TTM
$0
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$19,216,000
EBITDA
—
Free Cash Flow
$-7,323,375
Enterprise Value
$-19,304,290
Total Cash
$54,083,000
Total Debt
$1,945,000
Shares Out
9,953,155
Trailing EPS
$-0.23
Book Value
$9.07
ROE
-18.4%
ROA
-20.8%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 20,601,000 -16,074,000 -8,609,000 59,027,000 9,651,000 49,376,000 -5,283,000
Dec 2024 3,746,000 -37,117,000 -21,288,000 90,643,000 35,566,000 55,077,000 -24,009,000
Dec 2023 140,141,000 72,669,000 67,041,000 128,412,000 55,450,000 72,962,000 60,159,000
Dec 2022 5,091,000 -85,757,000 -62,809,000 87,810,000 84,577,000 3,233,000 -79,883,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$19,215,000
NetIncome TTM
$-10,235,000
OpCashFlow TTM
—
Assets (Latest)
$74,970,000
Forward EPS
$-2.31

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $2.82 · call volume: 101 · put volume: 5
Expected Move to 2026-12-18: ±$0.96 (34.04%) — implied range $1.86 – $3.78 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
PYRGF PyroGenesis Canada Inc. $28.34M $0.13 —
PMN ProMIS Neurosciences Inc. $28.88M $3.21 —
RDPTF Radiopharm Theranostics Ltd $28.89M $0.01 —
AYTU AYTU BIOPHARMA, INC $28.91M $2.66 —
BHST BIOHARVEST SCIENCES INC. $27.65M $1.22 —

News headlines (Yahoo Finance, 1h cache)

Scynexis: Q3 Earnings Snapshot
2026-11-05 13:27 · Yahoo
SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-05 13:20 · Yahoo
SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference
2026-10-29 12:00 · Yahoo
SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases
2026-10-22 12:00 · Yahoo
SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek
2026-10-21 20:05 · Yahoo
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2026-10-06 11:30 · Yahoo
Scynexis stock surges on $214M BARDA contract for SCY-247
2026-09-28 13:58 · Yahoo
Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract
2026-09-28 12:10 · Yahoo
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
2026-09-28 11:30 · Yahoo
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
2026-09-22 12:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.